Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Neuroendocrine × Capecitabine × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 54 Colorectal Neoplasms 41 Rectal Neoplasms 31 Stomach Neoplasms 24 Pancreatic Neoplasms 24 Neoplasm Metastasis 21 Neoplasms 17 Colonic Neoplasms 17 Triple Negative Breast Neoplasms 6 Esophageal Neoplasms 6 Liver Neoplasms 5 Brain Neoplasms 5 Adenocarcinoma 5 Head and Neck Neoplasms 3 Colorectal Cancer Metastatic 3 Carcinoma, Renal Cell 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasms, Unknown Primary 2 Gastrointestinal Neoplasms 2 Gallbladder Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Squamous Cell 2 Carcinoma 2 Biliary Tract Neoplasms 2 Bile Duct Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

iadademstat 1 Temozolomide 1 Sunitinib 1 Paclitaxel 1 Irinotecan 1 Fluorouracil 1 Everolimus 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡